연구용
제품 번호S2404
| 세포주 | 분석 유형 | 농도 | 배양 시간 | 제형 | 활성 설명 | PMID |
|---|---|---|---|---|---|---|
| KB cells | Growth inhibition assay | Compound concentration required to reduce the exponential growth of KB cells by 50%, CC50=12 μM | ||||
| MT-4 cells | Growth inhibition assay | Compound concentration required to reduce the exponential growth of MT-4 cells by 50%, CC50=7.4 μM | ||||
| Hepa lclc7 cells | Cytotoxicity assay | Cytotoxicity against mouse Hepa lclc7 cells, IC50=39 μM | ||||
| J774.1 cells | Function assay | 24 h | Inhibition of LPS-induced NO production in mouse J774.1 cells after 24 hrs by Griess reagent assay, IC50=29.3 μM | |||
| colon 26-L5 cells | Cytotoxicity assay | 72 h | Cytotoxicity against mouse colon 26-L5 cells after 72 hrs by MTT assay, IC50=21.8 μM | |||
| MCF7 cells | Cytotoxicity assay | 25-150 μM | 72 h | Cytotoxicity against human MCF7 cells at 25 to 150 uM after 72 hrs by MTT assay | ||
| CHO cells | Cytotoxicity assay | Cytotoxicity against CHO cells by MTT assay, IC50=45.9 μM | ||||
| human T47D cells | Function assay | 96 h | Estrogenic activity in human T47D cells assessed as drug level causing stimulation of cell proliferation equivalent to 10 pM estradiol after 96 hrs by alamar blue assay | |||
| MCF7 cells | Function assay | 96 h | Estrogenic activity in human MCF7 cells assessed as drug level causing stimulation of cell proliferation equivalent to 10 pM estradiol after 96 hrs by alamar blue assay | |||
| MCF7 cells | Function assay | Estrogenic activity in luciferase transfected human MCF7 cells assessed as drug level causing stimulation of cell proliferation equivalent to 10 pM estradiol by luciferase reporter gene assay | ||||
| mouse NIH3T3 cells | Function assay | 8 h | Inhibition of cobalt chloride-induced HIF-1 activation expressed in mouse NIH3T3 cells after 8 hrs by luciferase reporter gene assay, IC50=4.8 μM | |||
| OE21 cells | Cytotoxicity assay | 72 h | Cytotoxicity against human OE21 cells after 72 hrs by MTT assay, IC50=48 μM | |||
| U937 cells | Function assay | 5 ug/ml | 24 h | Antiinflammatory activity in human U937 cells assessed as inhibition of LPS-induced CCL5 secretion at 5 ug/ml after 24 hrs by ELISA relative to control | ||
| dog MDCK cells | Function assay | 20 ug/mL | 1 h | Antiviral activity against Influenza virus A/Puerto Rico/8/34 H1N1 infected in dog MDCK cells assessed as inhibition of viral replication at 20 ug/mL incubated at 1 hr post-infection measured after 24 hrs by hemagglutininating unit assay relative to control | ||
| dog MDCK cells | Function assay | 8 h | Inhibition of PKC/p38MAPK-mediated nuclear-cytoplasmic viral ribonucleoprotein export in dog MDCK cells infected with Influenza virus A/Puerto Rico/8/34 H1N1 measured at 8 hrs post-infection by inmmunofluorescence | |||
| NCI-H292 cells | Function assay | Inhibition of PKC-mediated PKD phosphorylation in human NCI-H292 cells infected with Influenza virus A/Puerto Rico/8/34 H1N1 measured at 6 hrs post-infection by immunoblotting analysis | ||||
| NCI-H292 cells | Function assay | Inhibition of PKC-mediated p38MAPK phosphorylation in human NCI-H292 cells infected with Influenza virus A/Puerto Rico/8/34 H1N1 measured at 6 hrs post-infection by immunoblotting analysis | ||||
| NCI-H292 cells | Function assay | Inhibition of PKC-mediated JNK phosphorylation in human NCI-H292 cells infected with Influenza virus A/Puerto Rico/8/34 H1N1 measured at 6 hrs post-infection by immunoblotting analysis | ||||
| dog MDCK cells | Function assay | Restoration of GSH level in dog MDCK cells infected with Influenza virus A/Puerto Rico/8/34 H1N1 measured at 24 hrs post-infection by DTNB-based colometric assay | ||||
| RBL-1 cells | Function assay | In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined, IC50=35 μM | ||||
| PC3 cells | Cytotoxicity assay | Cytotoxicity against human PC3 cells, IC50=46.4 μM | ||||
| HUVEC | Cytotoxicity assay | 48 h | Toxicity against HUVEC incubated for 48 hrs by MTT assay, IC50=41.17 μM | |||
| K562 cells | Cytotoxicity assay | 48 h | Antitumor activity against human K562 cells incubated for 48 hrs by MTT assay, IC50=29.27 μM | |||
| Hepa-1c1c7 cells | Function assay | Induction of quinone reductase activity in mouse Hepa-1c1c7 cells assessed as drug level required to double enzyme activity | ||||
| Hepa lclc7 cells | Function assay | Induction of mouse quinone reductase in mouse Hepa lclc7 cells assessed as concentration required to double enzyme activity | ||||
| U937 cells | Function assay | 5 ug/ml | Inhibition of LPS-induced AP-1 activation in human U937 cells at 5 ug/ml after 1 hr relative to control | |||
| 클릭하여 더 많은 세포주 실험 데이터 보기 | ||||||
| 분자량 | 256.25 | 화학식 | C15H12O4 |
보관 (수령일로부터) | |
|---|---|---|---|---|---|
| CAS 번호 | 961-29-5 | SDF 다운로드 | 원액 보관 |
|
|
| 동의어 | N/A | Smiles | C1=CC(=CC=C1C=CC(=O)C2=C(C=C(C=C2)O)O)O | ||
|
In vitro |
Ethanol : 26 mg/mL
DMSO
: 12 mg/mL
(46.82 mM)
Water : Insoluble |
|
In vivo |
|||||
1단계: 아래 정보 입력 (권장: 실험 중 손실을 고려하여 추가 동물 포함)
2단계: 생체 내 제형 입력 (이것은 계산기일 뿐 제형이 아닙니다. 용해도 섹션에 생체 내 제형이 없는 경우 먼저 당사에 문의하십시오.)
계산 결과:
작업 농도: mg/ml;
DMSO 원액 준비 방법: mg 약물 사전 용해 μL DMSO ( 원액 농도 mg/mL, 농도가 해당 약물 배치의 DMSO 용해도를 초과하는 경우 먼저 당사에 문의하십시오. )
생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가μL PEG300, 혼합하고 투명하게 한 다음 추가μL Tween 80, 혼합하고 투명하게 한 다음 추가 μL ddH2O, 혼합하고 투명하게 합니다.
생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가 μL 옥수수 기름, 혼합하고 투명하게 합니다.
참고: 1. 다음 용매를 추가하기 전에 액체가 투명한지 확인하십시오.
2. 용매를 순서대로 추가해야 합니다. 다음 용매를 추가하기 전에 이전 추가에서 얻은 용액이 투명한 용액인지 확인해야 합니다. 와동, 초음파 또는 뜨거운 물 중탕과 같은 물리적 방법을 사용하여 용해를 도울 수 있습니다.
| Targets/IC50/Ki |
Aldose reductase
(Cell-free assay) 320 nM
|
|---|---|
| 시험관 내(In vitro) |
Isoliquiritigenin은 320 nM의 IC50으로 쥐 렌즈 aldose Reductase를 억제하고 2.0 μM의 IC50으로 사람 적혈구에서 솔비톨 축적을 억제함으로써 당뇨병 합병증 예방에 효과적일 수 있습니다. 이 화합물은 또한 8.1 μM의 IC50으로 모노 및 디페놀라제 티로시나제 활성을 억제함으로써 피부 미백제로 작용할 수 있습니다. 이는 DU145 및 LNCaP 전립선암 세포주에서 세포 주기 정지 및 세포 성장 억제를 유도합니다. 이 화학물질은 세포 내 유리 칼슘 농도를 증가시키고 미토콘드리아 막 전위(Deltapsi(m))를 감소시킴으로써 인간 위암 MGC-803 세포의 세포사멸을 유도합니다.
|
| 생체 내(In vivo) |
LD50: 쥐 >6g/kg (i.g.)
|
참조 |
|